Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
All voices matter
pharmaceuticals
Chinese AI biotech deals hit $75B as US scrutiny grows
Chinese biotech firms powered by artificial intelligence have struck out-licensing deals worth $75 billion in the first five months of 2026, a figure that stood at zero before 2020, underscoring how rapidly China has emerged as a global hub for…
Novo Nordisk demands price cuts from suppliers amid margin squeeze
Novo Nordisk has written to its suppliers requesting price reductions as the Danish pharmaceutical giant grapples with mounting cost pressures in a rapidly changing weight-loss drug market, according to a report by MedWatch on Wednesday. The correspondence gave suppliers only…
Anthropic launches Claude Science workbench for researchers
Anthropic on Tuesday began rolling out Claude Science, an AI-powered workbench designed to give scientists a single environment for research across biology, chemistry, genomics, and drug discovery. The product was announced at "The Briefing: AI for Science," a live event…
FDA approves Trodelvy for first-line metastatic breast cancer
The U.S. Food and Drug Administration on Wednesday approved Gilead Sciences' Trodelvy (sacituzumab govitecan-hziy) for the first-line treatment of metastatic triple-negative breast cancer, a decision that establishes the antibody-drug conjugate as a new standard of care for one of the…
First cannabis-based chronic pain drug wins approval in Germany and Austria
German biopharmaceutical company Vertanical announced on Monday that Exilby (VER-01), a cannabis-derived oral tincture, has received marketing authorization in Germany for the treatment of chronic low back pain with a neuropathic component, making it the first cannabis-based medication explicitly approved…
Gilead, Merck once-weekly HIV pill succeeds in Phase 3
Gilead Sciences and Merck announced on Sunday that their investigational once-weekly combination pill of islatravir and lenacapavir met its primary efficacy endpoint in two Phase 3 trials, marking a potential milestone in HIV treatment as the first long-acting oral therapy…
AstraZeneca obesity pill moves to Phase III after nearly 12% weight loss in mid-stage trials
AstraZeneca unveiled full results from two mid-stage trials of its experimental oral obesity drug elecoglipron on Monday at the American Diabetes Association's 2026 Scientific Sessions in New Orleans, revealing that the once-daily pill produced an average body weight reduction of…